PROK
Price
$1.98
Change
-$0.15 (-7.04%)
Updated
Jan 30 closing price
Capitalization
280.26M
Intraday BUY SELL Signals
SABS
Price
$4.39
Change
-$0.03 (-0.68%)
Updated
Jan 30 closing price
Capitalization
208.04M
Intraday BUY SELL Signals
Interact to see
Advertisement

PROK vs SABS

Header iconPROK vs SABS Comparison
Open Charts PROK vs SABSBanner chart's image
ProKidney
Price$1.98
Change-$0.15 (-7.04%)
Volume$1.63M
Capitalization280.26M
SAB Biotherapeutics
Price$4.39
Change-$0.03 (-0.68%)
Volume$117K
Capitalization208.04M
PROK vs SABS Comparison Chart in %
PROK
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PROK vs. SABS commentary
Feb 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PROK is a Buy and SABS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 02, 2026
Stock price -- (PROK: $1.98 vs. SABS: $4.39)
Brand notoriety: PROK and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PROK: 140% vs. SABS: 32%
Market capitalization -- PROK: $280.26M vs. SABS: $208.04M
PROK [@Biotechnology] is valued at $280.26M. SABS’s [@Biotechnology] market capitalization is $208.04M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.22B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PROK’s FA Score shows that 0 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • PROK’s FA Score: 0 green, 5 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, SABS is a better buy in the long-term than PROK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PROK’s TA Score shows that 3 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • PROK’s TA Score: 3 bullish, 4 bearish.
  • SABS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SABS is a better buy in the short-term than PROK.

Price Growth

PROK (@Biotechnology) experienced а -8.76% price change this week, while SABS (@Biotechnology) price change was +8.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.27%. For the same industry, the average monthly price growth was +3.46%, and the average quarterly price growth was +33.81%.

Industries' Descriptions

@Biotechnology (-4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PROK($280M) has a higher market cap than SABS($208M). SABS YTD gains are higher at: 17.380 vs. PROK (-11.607). SABS has higher annual earnings (EBITDA): 22.1M vs. PROK (-149.22M). PROK has more cash in the bank: 272M vs. SABS (111M). PROK has less debt than SABS: PROK (4.24M) vs SABS (6.19M). PROK has higher revenues than SABS: PROK (744K) vs SABS (0).
PROKSABSPROK / SABS
Capitalization280M208M135%
EBITDA-149.22M22.1M-675%
Gain YTD-11.60717.380-67%
P/E RatioN/AN/A-
Revenue744K0-
Total Cash272M111M245%
Total Debt4.24M6.19M68%
TECHNICAL ANALYSIS
Technical Analysis
PROKSABS
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
67%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 11 days ago
74%
Bullish Trend 4 days ago
74%
Declines
ODDS (%)
Bearish Trend 7 days ago
81%
Bearish Trend 24 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
PROK
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WOSGF7.22N/A
+0.06%
Watches of Switzerland Group PLC
GVFF6.75N/A
N/A
Greenville Federal Financial Corp.
SYANY18.10N/A
N/A
Sydbank A/S
CLLKF1.98N/A
N/A
BICO GROUP AB
RLXXF34.99-1.21
-3.34%
RELX PLC

PROK and

Correlation & Price change

A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RLYB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RLYB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROK
1D Price
Change %
PROK100%
-7.04%
RLYB - PROK
45%
Loosely correlated
-3.86%
NRIX - PROK
39%
Loosely correlated
-6.08%
APGE - PROK
38%
Loosely correlated
-6.39%
KYMR - PROK
37%
Loosely correlated
-1.65%
ZYME - PROK
37%
Loosely correlated
+0.67%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with CYPH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then CYPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-0.68%
CYPH - SABS
36%
Loosely correlated
+6.73%
TECX - SABS
34%
Loosely correlated
-3.38%
INKT - SABS
28%
Poorly correlated
-3.80%
PROK - SABS
28%
Poorly correlated
-7.04%
IMVT - SABS
26%
Poorly correlated
-1.70%
More